Fig. 1
From: Proteins lead the way: JAK inhibitors as a new treatment option in toxic epidermal necrolysis
Spatial proteomics identifies JAKi as a new treatment option in TEN. a Experimental approach of spatial proteomics in maculopapular rash (MPR), drug eosinophilia with systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) using deep visual proteomics. b Summary of main findings in TEN by Nordmann et al. highlighting epidermal cell death and activation of STAT1 through type I and type II IFN signaling with infiltrating macrophages and T cells marked by high expression of IFN-induced genes. The cellular origin of type I/II IFN has not been investigated in this study. c Mechanism of JAKi in type I (IFNα/β) and type II (IFNγ) IFN signaling. d Treatment of TEN (n = 7) with JAKi and observed outcomes. Abbreviations: JAK Janus Kinase, JAKi JAK inhibitor, STAT Signal Transducer and Activator of Transcription, IFNAR Interferon alpha/beta Receptor, IFNGR Interferon gamma Receptor, IRF Interferon Regulatory Factor, ISGF3 Interferon-stimulated gene factor 3, ISRE Interferon Stimulation Response Element, ISG Interferon Stimulated Gene, GAS Gamma Interferon Activation Site. Created in BioRender. Kahlenberg, M. (2025) https://BioRender.com/a16k451
